EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vireo Growth's EBITDA for the
three
months ended in Mar. 2026 was €8.9 Mil. Vireo Growth's Revenue for the
three
months ended in Mar. 2026 was €91.9 Mil. Therefore, Vireo Growth's EBITDA margin for the quarter that ended in Mar. 2026 was 9.70%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vireo Growth EBITDA Margin % Related Terms
Vireo Growth EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vireo Growth's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vireo Growth's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a EBITDA Margin % of 9.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #640 out of 955 companies in the Drug Manufacturers industry, placing it in the top 67%.
Is Vireo Growth's EBITDA Margin % too high?
Vireo Growth's current EBITDA Margin % is 9.70%. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Vireo Growth's value of 9.70% is 21.7% below this industry median. Based on the distribution chart, Vireo Growth ranks #640 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #640 out of 955 companies for EBITDA Margin %. This places Vireo Growth in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Vireo Growth's value of 9.70% is 21.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current EBITDA Margin % of 9.70% is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current EBITDA Margin % is 9.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current EBITDA Margin % is 9.70% and 21.7% below the Drug Manufacturers industry median of 12.39. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current EBITDA Margin % is 9.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
EBITDA Margin %: 9.70%
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 21.7% below the Drug Manufacturers median (#640 of 955)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
